利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.024 秒)

    Method of determining whether an agent modulates glycosyl sulfotransferase-3
    1.
    发明授权
    Method of determining whether an agent modulates glycosyl sulfotransferase-3 失效
    确定药剂是否调节糖基磺基转移酶-3的方法

    公开(公告)号：US06365365B1

    公开(公告)日：2002-04-02

    申请号：US09190911

    申请日：1998-11-12

    申请人： Annette Bistrup ,  Steven D. Rosen ,  Kirsten Tangemann ,  Stefan Hemmerich

    发明人： Annette Bistrup ,  Steven D. Rosen ,  Kirsten Tangemann ,  Stefan Hemmerich

    IPC分类号： C12Q148

    CPC分类号： C12N9/13 ,  A01K2217/05 ,  A61K38/00

    摘要： A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-3 or KSGal6ST, or homologues thereof.

    摘要翻译： 提供了在高内皮细胞（GST-3）中表达的新型人类糖基转移酶及与其相关的多肽，以及编码其的核酸组合物。 主题多肽和核酸组合物可用于各种应用，包括研究，诊断和治疗剂筛选应用。 还提供了抑制选择素介导的结合事件的方法和治疗与其相关的疾病状况的方法，特别是通过施用GST-3或KSGal6ST中的至少一种的抑制剂或其同系物。

    Glycosyl sulfotransferase-3
    2.
    发明授权
    Glycosyl sulfotransferase-3 失效
    糖基磺基转移酶-3

    公开(公告)号：US06967093B2

    公开(公告)日：2005-11-22

    申请号：US09816825

    申请日：2001-03-22

    申请人： Annette Bistrup ,  Steven D. Rosen ,  Stefan Hemmerich

    发明人： Annette Bistrup ,  Steven D. Rosen ,  Stefan Hemmerich

    IPC分类号： A61K38/00 ,  C12N9/10 ,  C12N15/54 ,  C12P21/06 ,  C07H21/04 ,  C12N9/00

    CPC分类号： C12N9/13 ,  A01K2217/05 ,  A61K38/00

    摘要： A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.

    摘要翻译： 提供了在高内皮细胞（GST-3）中表达的新型人类糖基转移酶及与其相关的多肽，以及编码其的核酸组合物。 主题多肽和核酸组合物可用于各种应用，包括研究，诊断和治疗剂筛选应用。 还提供了抑制选择素介导的结合事件的方法和治疗与之相关的疾病状况的方法。

    HEC-G1CNAC6ST
    4.
    发明授权
    HEC-G1CNAC6ST 失效

    公开(公告)号：US06933142B1

    公开(公告)日：2005-08-23

    申请号：US09645078

    申请日：2000-08-23

    申请人： Annette Bistrup ,  Steven D. Rosen ,  Stefan Hemmerich

    发明人： Annette Bistrup ,  Steven D. Rosen ,  Stefan Hemmerich

    IPC分类号： A01K67/027 ,  A61K38/00 ,  A61K45/00 ,  A61K48/00 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C12N1/15 ,  C12N1/21 ,  C12N5/10 ,  C12N9/10 ,  C12N15/09 ,  C12N15/54 ,  C12Q1/48 ,  C07K14/435

    CPC分类号： C12N9/13 ,  A01K2217/05 ,  A61K38/00

    摘要： Mammalian glycosylsulfotransferases expressed in high endothelial cells (HEC-GLCNAC6ST) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of HEC-GLCNAC6ST or KSGal6ST, or homologues thereof.

    摘要翻译： 提供了在高内皮细胞（HEC-GLCNAC6ST）中表达的哺乳动物糖基转移酶和与其相关的多肽，以及编码其的核酸组合物。 主题多肽和核酸组合物可用于各种应用，包括诊断和治疗剂筛选应用。 还提供了抑制选择素介导的结合事件的方法和治疗与之相关的疾病状况的方法，特别是通过施用HEC-GLCNAC6ST或KSGal6ST中的至少一种的抑制剂或其同系物。

    Sulfated ligands for l-selectin and methods of treating inflammation
    5.
    发明授权
    Sulfated ligands for l-selectin and methods of treating inflammation 失效
    L-选择素的硫酸化配体和治疗炎症的方法

    公开(公告)号：US5489578A

    公开(公告)日：1996-02-06

    申请号：US432849

    申请日：1996-05-02

    申请人： Steven D. Rosen ,  Stefan Hemmerich

    发明人： Steven D. Rosen ,  Stefan Hemmerich

    IPC分类号： A61K38/45 ,  C07H3/06 ,  A61K31/715 ,  A61K31/70 ,  A61K38/00 ,  A61K39/00

    CPC分类号： A61K38/45 ,  C07H3/06

    摘要： Sulfated oligosaccharides which bind to L-selectin receptors and act as agonists are formulated into pharmaceutical formulations and administered by injection to treat inflammation. Compounds which act as metabolic inhibitors of carbohydrate sulfation and inhibit the sulfation of naturally occurring ligands for L-selectin receptors are administered locally by injection to alleviate and/or prevent inflammation. The sulfated oligosaccharides can be administered in combination with the chlorates and sulfatases in order to obtain a combined effect which is useful in preventing and/or alleviating inflammation. A preferred group of ligands are obtained by the hydrolysis of GlyCAM-1 by separation procedures including high pH anion exchange chromatography. The invention describes compounds that have the recognition determinants for L-selectin on GlyCAM-1 as Galactose-6-sulfate and/or N-acetylglucosamine-6-sulfate, in concert with sialic acid and fucose.

    摘要翻译： 结合L-选择素受体并作为激动剂的硫酸化寡糖被配制成药物制剂并通过注射给药以治疗炎症。 充当碳水化合物硫酸化代谢抑制剂并抑制天然存在的L-选择素受体配体的硫酸化的化合物通过注射局部施用以减轻和/或预防炎症。 硫酸化寡糖可以与氯酸盐和硫酸酯酶组合施用，以获得可用于预防和/或减轻炎症的组合效果。 通过包括高pH阴离子交换色谱法的分离方法水解GlyCAM-1，可以获得优选的配体。 本发明描述了与唾液酸和岩藻糖一致的具有作为半乳糖-6-硫酸盐和/或N-乙酰氨基葡萄糖-6-硫酸盐的GlyCAM-1上L-选择素的识别决定簇的化合物。

    Glycosly sulfortransferase-3
    7.
    发明授权
    Glycosly sulfortransferase-3 失效
    糖基转移酶-3

    公开(公告)号：US06265192B1

    公开(公告)日：2001-07-24

    申请号：US09045284

    申请日：1998-03-20

    申请人： Annette Bistrup ,  Steven D. Rosen ,  Stefan Hemmerich

    发明人： Annette Bistrup ,  Steven D. Rosen ,  Stefan Hemmerich

    IPC分类号： C12P2106

    CPC分类号： C12N9/13 ,  A01K2217/05 ,  A61K38/00

    摘要： A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.

    摘要翻译： 提供了在高内皮细胞（GST-3）中表达的新型人类糖基转移酶及与其相关的多肽，以及编码其的核酸组合物。 主题多肽和核酸组合物可用于各种应用，包括研究，诊断和治疗剂筛选应用。 还提供了抑制选择素介导的结合事件的方法和治疗与之相关的疾病状况的方法。

    Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
    8.
    发明授权
    Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor 失效
    通过施用特异性硫酸酯酶和/或硫酸化抑制剂来治疗炎症

    公开(公告)号：US5925349A

    公开(公告)日：1999-07-20

    申请号：US916766

    申请日：1997-08-19

    申请人： Steven D. Rosen ,  Stefan Hemmerich ,  Yasuyuki Imai

    发明人： Steven D. Rosen ,  Stefan Hemmerich ,  Yasuyuki Imai

    IPC分类号： A61K38/45 ,  A61K38/46 ,  A61P29/00 ,  A61K38/47 ,  A61K33/04 ,  A61K33/20 ,  A61K38/43

    CPC分类号： A61K38/465 ,  C12Y301/06004

    摘要： Compositions are administered to a patient (preferably by injection and locally) to treat a variety of conditions including inflammation associated with trauma and with certain aspects of diseases such as rheumatoid arthritis, psoriasis, insulin-dependent diabetes, cutaneous lymphomas, duodenal ulcer, chronic proctitis, lymphocytic thyroiditis, hemorphagic shock, reperfusion injury during transplantation and multiple sclerosis. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier. The active component is a chlorate or selenate which inhibits the natural biochemical sulfation process and/or a sulfatase enzyme which removes a sulfate from a specific position of a saccharide molecule which makes up a part of a natural ligand for L-selectin. Removal of the sulfate from the ligand hinders the ability of the ligand to bind to its natural receptor (i.e. L-selectin) and thereby hinders a biochemical chain of events which results in inflammation.

    摘要翻译： 将组合物施用于患者（优选通过注射和局部施用）以治疗包括与创伤相关的炎症以及诸如类风湿性关节炎，牛皮癣，胰岛素依赖性糖尿病，皮肤淋巴瘤，十二指肠溃疡，慢性直肠炎等疾病的某些方面的各种病症 ，淋巴细胞性甲状腺炎，血管性休克，移植期间的再灌注损伤和多发性硬化。 该组合物是药学上可接受的可注射制剂，其包括药学上可接受的载体中的活性成分。 活性组分是氯化物或硒酸盐，其抑制天然生化硫酸化过程和/或硫酸酯酶，其从构成L-选择素的天然配体的一部分的糖分子的特定位置去除硫酸盐。 从配体中除去硫酸盐阻碍配体结合其天然受体（即L-选择蛋白）的能力，从而阻碍导致炎症的事件的生物化学链。

    Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
    9.
    发明授权
    Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor 失效
    通过施用特异性硫酸酯酶和/或硫酸化抑制剂来治疗炎症

    公开(公告)号：US5695752A

    公开(公告)日：1997-12-09

    申请号：US496857

    申请日：1995-06-30

    申请人： Steven D. Rosen ,  Stefan Hemmerich ,  Yasuyuki Imai

    发明人： Steven D. Rosen ,  Stefan Hemmerich ,  Yasuyuki Imai

    IPC分类号： A61K38/45 ,  A61K38/46 ,  A61P29/00 ,  A61K38/47 ,  A61K38/43 ,  C12N9/24

    CPC分类号： A61K38/465 ,  C12Y301/06004

    摘要： Compositions are administered to a patient (preferably by injection and locally) to treat a variety of conditions including inflammation associated with trauma and with certain aspects of diseases such as rheumatoid arthritis, psoriasis, insulin-dependent diabetes, cutaneous lymphomas, duodenal ulcer, chronic proctitis, lymphocytic thyroidiris, hemorphagic shock, reperfusion injury during transplantation and multiple sclerosis. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier. The active component is a chlorate or selenate which inhibits the natural biochemical sulfation process and/or a sulfatase enzyme which removes a sulfate from a specific position of a saccharide molecule which makes up a part of a natural ligand for L-selectin. Removal of the sulfate from the ligand hinders the ability of the ligand to bind to its natural receptor (i.e. L-selectin) and thereby hinders a biochemical chain of events which results in inflammation.

    摘要翻译： 将组合物施用于患者（优选通过注射和局部施用）以治疗包括与创伤相关的炎症以及诸如类风湿性关节炎，牛皮癣，胰岛素依赖性糖尿病，皮肤淋巴瘤，十二指肠溃疡，慢性直肠炎等疾病的某些方面的各种病症 ，淋巴细胞性甲状腺炎，血管性休克，移植期间的再灌注损伤和多发性硬化。 该组合物是药学上可接受的可注射制剂，其包括药学上可接受的载体中的活性成分。 活性组分是氯化物或硒酸盐，其抑制天然生化硫酸化过程和/或硫酸酯酶，其从构成L-选择素的天然配体的一部分的糖分子的特定位置去除硫酸盐。 从配体中除去硫酸盐阻碍配体结合其天然受体（即L-选择蛋白）的能力，从而阻碍导致炎症的事件的生物化学链。

    Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
    10.
    发明授权
    Cromolyn binding protein in highly purifed form, and methods for the isolation thereof 失效
    高度纯化形式的克罗莫仑结合蛋白及其分离方法

    公开(公告)号：US4996296A

    公开(公告)日：1991-02-26

    申请号：US78134

    申请日：1987-07-27

    申请人： Israel Pecht ,  Stefan Hemmerich

    发明人： Israel Pecht ,  Stefan Hemmerich

    IPC分类号： C07K14/705 ,  C07K16/28

    CPC分类号： C07K14/705 ,  C07K16/28 ,  Y10S530/802 ,  Y10S530/83

    摘要： Substantially pure cromolyn binding protein is prepared by means of affinity chromatography of cromolyn derivatives bound to insoluble matrices. Aminocromolyn is prepared by a six-step synthesis and amine derivatives thereof are prepared by conventional means. Obtaining a compound having an amine group instead of the OH group at the 2-carbon of the propane link of cromolyn permits many kinds of reactions without interfering with the portion of the cromolyn molecule with causes its pharmacological activity. The cromolyn derivatives can be conjugated to proteins such as BSA by means of glutaraldehyde cross-linking and such conjugates can be covalently bound to agarose beads. Cromolyn binding protein can be isolated by passing lysates of RBL-2H3 cells through chromatographic columns packed with such beads. The cromolyn binding protein can be further purified by means of lectin-agarose columns.

    摘要翻译： 通过亲和层析与不溶性基质结合的色甘酸衍生物制备基本纯的色甘酸结合蛋白。 氨基木聚糖通过六步合成制备，其胺衍生物通过常规方法制备。 在色原醇的丙烷连接的2-碳上获得具有胺基而不是OH基的化合物允许多种反应，而不会干扰色甘酸分子的部分，导致其药理活性。 色甘酸衍生物可以通过戊二醛交联与蛋白质例如BSA缀合，并且这种缀合物可以共价结合到琼脂糖珠上。 可以通过将RBL-2H3细胞的裂解物通过用这种珠填充的色谱柱分离克隆体结合蛋白。 色甘酸结合蛋白可以通过凝集素 - 琼脂糖柱进一步纯化。